W

bioLLM/wiki

LLM-Synthesized Biotech Database

Live

MS4A1

MS4A1

Overview

MS4A1 encodes CD20, a B-cell surface protein that is widely used as a lineage marker in immunology and hematologic oncology. CD20 is expressed on mature B cells and is absent from most other normal tissues, which has made it an important biomarker and therapeutic target in B-cell malignancies and immune-mediated diseases. In biomedical research, MS4A1 is commonly used to identify B-cell populations, assess B-cell depletion, and evaluate antigen expression patterns in lymphoma and related settings.

Functionally, CD20 is best known as a cell-surface target for antibody-based therapies and engineered cellular immunotherapies. Because it is retained on many malignant B cells, MS4A1/CD20 has become central to strategies such as anti-CD20 antibodies, CD20-directed CAR-T cells, and tandem or bispecific CD19/20 approaches designed to reduce antigen escape. Recent studies also use CD20 in spatial transcriptomic profiling to define B-cell and plasma cell-like phenotypes within the tumor microenvironment.

Recent Publications Focus

Below is a summary of the newest research publications targeting MS4A1 (sorted by publication date).

  • 2026-06-09 — Digital spatial profiling in diffuse large B-cell lymphoma

    • This study used spatially resolved transcriptomics to characterize distinct plasma cell-like phenotypes in diffuse large B-cell lymphoma, with CD20 as one of the defining markers alongside HLA-DRA and PRDM1.
    • The authors identified four phenotypic states based on combinations of CD20, HLA-DRA, and PRDM1 expression: CD20+HLA-DRA+PRDM1-, CD20+HLA-DRA+PRDM1+, CD20+HLA-DRA-PRDM1-, and CD20+HLA-DRA-PRDM1+.
    • The work highlights the value of spatial transcriptomics for resolving intratumoral heterogeneity and shows that CD20 remains informative even in plasma cell-like tumor states.

  • 2026-05-22 — Erythrocyte patch for enhanced B cell depletion therapy

    • This study introduced CD20 EryPatches, a therapy designed to adhere to B cells and anchor on CD20 receptors across extensive cell surface areas.
    • The approach is explicitly aimed at improving B cell depletion therapy by leveraging CD20 as the binding target.
    • The publication positions CD20-targeting as a platform for more effective cell-surface engagement in B-cell-directed treatment strategies.

  • 2026-05-17 — Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma

    • This clinical study examined dual-target CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma and paired clinical outcomes with spatial transcriptomic profiling.
    • The authors noted that dual targeting of CD19 and CD20 may mitigate antigen loss, a key mechanism of resistance in B-cell immunotherapy.
    • The study reinforces the rationale for combining MS4A1/CD20 with CD19 molecule targeting to improve durability of response in B-cell malignancies.

  • 2026-04-28 — Next-generation CD179a-CAR-T cells in preclinical B-cell malignancies

    • Although the main focus was CD179a-CAR-T cells, the paper explicitly discussed conventional CAR constructs targeting CD19 or CD20.
    • The authors stated that these conventional CD19- or CD20-directed CARs often result in off-tumor toxicity due to shared antigen expression on healthy B cells.
    • This contextualizes CD20 as a clinically important but biologically non-exclusive B-cell antigen, underscoring the challenge of balancing efficacy with safety in cancer immunotherapy.

  • 2026-04-14 — Zamtocabtagene autoleucel in relapsed/refractory B-NHL

    • This first-in-human phase 1 trial evaluated zamtocabtagene autoleucel, a noncryopreserved tandem CD20-CD19-directed CAR T-cell therapy, in relapsed/refractory B-cell non-Hodgkin’s lymphoma.
    • The study was designed to reduce selective pressure on the CD19 antigen by incorporating CD20 targeting into the CAR construct.
    • The tandem design reflects a broader strategy to address antigen escape and improve the robustness of B-cell–directed cellular immunotherapy.

  • 2026-05-22 — Multi-omics analysis of Danggui Buxue decoction in benzene-induced blood deficiency syndrome

    • In a multi-omics study, the authors reported that the treatment reshaped the immune microenvironment by enhancing immune-related pathways, including MHC class II antigen presentation and immune cell activation.
    • CD20 was among the immune cell activation markers mentioned, together with CD22, CD37, and CD8a.
    • While not a direct CD20-targeting therapy, the study places MS4A1/CD20 within a broader immune-reconstitution context and links it to restoration of immune homeostasis.

  • 2026-06-01 and related non-target-focused publications

    • Several other listed publications mention B1, B3, collagen, polyvinyl alcohol, sewage, electro-flocculated wastewater, or microbial consortium systems, but these contexts do not provide direct MS4A1/CD20-targeted findings.
    • They are therefore not interpreted as evidence for a specific biological role of MS4A1 in those studies.

Overall, the recent literature continues to support MS4A1/CD20 as a major B-cell biomarker and therapeutic target. The newest studies emphasize three recurring themes: improved spatial resolution of CD20-positive tumor states, dual-antigen strategies such as CD19/20 CAR-T therapy to reduce antigen loss, and engineered CD20-directed platforms intended to enhance B-cell depletion while managing the safety challenges associated with targeting normal B cells.

Background PMIDs

  • [PMID 41512222]

Method PMIDs

  • [PMID 42206807]

Result PMIDs

  • [PMID 42080542]

Target PMIDs

  • [PMID 41886633]
  • [PMID 42097433]
  • [PMID 42174699]
  • [PMID 42160424]
  • [PMID 42144261]
  • [PMID 42047877]
Content is generated using Large Language Models (LLMs) and may contain errors or hallucinations. Experts periodically review it to verify accuracy and maintain database integrity.